Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Nash, the one-time favourite therapy area for biopharma speculators, is back.
The Bristol-Myers Squibb and Amicus drugs face approval decisions next week.
Deepmind plans more rigorous trials of its ophthalmology AI after early successes.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
New data for heart failure pill could clear the way for use in less severely ill patients.
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
A looming interim analysis could make Amryt a player in epidermolysis bullosa – and boost its deal-making ambitions.
If investors have visions of Luxturna-like prices they might need to blink and look again.
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.